NPPB and cancer: Baseline risk assessment is recommended to all patients who will receive a cancer treatment with potential cardiotoxicity and includes, among others, cardiac history, CV risk factors, cardiac troponin, and B-type natriuretic peptide (BNP) or its N-terminal fragment (NT-proBNP), electrocardiogram and echocardiography, as well as cancer treatment history [94].